CIBMTR Reporting Implementation Guide
0.1.6 - Trial Use 1

This page is part of the CIBMTR Reporting Implementation Guide (v0.1.6: Release Draft) based on FHIR R4. This is the current published version. For a full list of available versions, see the Directory of published versions

Form 2450

Guidance: Form 2450 - Post-TED

Transplant centers participating in the CIBMTR must submit a Post-TED Form for recipients who meet any of the following criteria:

  • Recipient receives a transplant at a United States center designated as a TED-only center.
  • Recipient receives a transplant at a United States center designated as Comprehensive Report Form center, but has been assigned to the TED track by the Form Selection Algorithm.
  • Recipient receives an allogeneic transplant at a United States center designated as Comprehensive Report Form center, but has not consented to participate in research.
  • Recipient receives a transplant at an international center, has consented to participate in research, and has been assigned to the TED track by the Form Selection Algorithm.

See Form 2450 manual for more information about this CIBMTR form.

The follow describes sections in Form 2450, and what FHIR Resources/Profiles and Valuesets are used to answer the questions those sections. Examples are also given.

Survival

  • Comment:
  • Resources/Profiles:
    • Encounter? (for date of contact?)
    • Condition? (for survival status?)
  • ValueSets:
    • Survival status
  • Examples:
    • 100 Day Date of Contact (found in manual page)
    • 6 Month Date of Contact
    • 1 Year Date of Contact

Subsequent Transplant

  • Comment:
  • Resource/Profiles:
  • ValueSets:
    • Reason for subsequent HCT
    • Source of HSCs
  • Examples:

Initial ANC Recovery

  • Comment:
  • Resource/Profiles:
  • ValueSets:
  • Examples:

Initial Platelet Recovery

  • Comment:
  • Resource/Profiles:
  • ValueSets:
  • Examples:

Graft versus Host Disease (Allogeneic Only)

  • Comment:
  • Resource/Profiles:
  • ValueSets:
  • Examples:

Liver Toxicity Prophylaxis

  • Comment:
  • Resource/Profiles:
  • ValueSets:
  • Examples:

Veno-occlusive disease (VOD) / Sinusoidal obstruction syndrome (SOS)

  • Comment:
  • Resource/Profiles:
  • ValueSets:
  • Examples:

Infection

  • Comment:
  • Resource/Profiles:
  • ValueSets:
  • Examples:

New Malignancy, Lymphoproliferative or Myeloproliferative Disorder

  • Comment:
  • Resource/Profiles:
  • ValueSets:
  • Examples:

Chimerism Studies (Cord Blood Units, Beta Thalassemia, and Sickle Cell Disease Only)